{"id":64157,"date":"2026-09-09T14:17:01","date_gmt":"2026-09-09T12:17:01","guid":{"rendered":"https:\/\/carlosoconnor.es\/?p=64157"},"modified":"2026-09-09T14:17:06","modified_gmt":"2026-09-09T12:17:06","slug":"impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos","status":"publish","type":"post","link":"https:\/\/carlosoconnor.es\/en\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/","title":{"rendered":"Impacto de los agonistas del receptor de GLP-1 en pacientes con AOS."},"content":{"rendered":"<p class=\"wp-block-paragraph\">Esta reciente revisi\u00f3n publicada en Otolaryngology\u2013Head and Neck Surgery eval\u00faa el impacto de los agonistas del receptor de GLP-1 (como liraglutida y tirzepatida) en pacientes con AOS. Los resultados demuestran que estos f\u00e1rmacos reducen el \u00edndice de apnea-hipopnea (IAH) en una media de 12,4 eventos por hora en comparaci\u00f3n con los grupos control, adem\u00e1s de inducir p\u00e9rdidas significativas de peso (un 12,5% superior), reducir la circunferencia abdominal y mejorar las cifras de presi\u00f3n arterial. Lo m\u00e1s relevante desde el punto de vista cl\u00ednico es que esta mejor\u00eda en la gravedad de la apnea ocurre independientemente de si el paciente utiliza o no la terapia con CPAP, consolidando a la v\u00eda metab\u00f3lica como una alternativa terap\u00e9utica sist\u00e9mica muy potente.Sin embargo, reducir el tejido adiposo peri-far\u00edngeo mediante el control metab\u00f3lico resuelve solo una parte del problema: la funci\u00f3n neuromuscular de la v\u00eda a\u00e9rea superior sigue requiriendo un abordaje directo. En este contexto, la terapia miofuncional orofacial se presenta como el complemento biomec\u00e1nico ideal y no invasivo dentro de este nuevo paradigma multimodal.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Enlace de referencia: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42611692\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/42611692\/<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">#MedicinaDelSue\u00f1o #Otorrinolaringologia #ApneaDelSue\u00f1o #TerapiaMiofuncional #GLP1 #Tirzepatida #SaludMetabolica #AOS #SaludRespiratoria #Sue\u00f1oReparador<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428-1024x683.png\" alt=\"17593926592428\" class=\"wp-image-64158\" srcset=\"https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428-1024x683.png 1024w, https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428-18x12.png 18w, https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428-300x200.png 300w, https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428-369x246.png 369w, https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428-768x512.png 768w, https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428-410x273.png 410w, https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428-840x560.png 840w, https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428-600x400.png 600w, https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428.png 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">17593926592428<\/figcaption><\/figure>","protected":false},"excerpt":{"rendered":"<p>Esta reciente revisi\u00f3n publicada en Otolaryngology\u2013Head and Neck Surgery eval\u00faa el impacto de los agonistas del receptor de GLP-1 (como liraglutida y tirzepatida) en pacientes con AOS. Los resultados demuestran&hellip;<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-64157","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Impacto de los agonistas del receptor de GLP-1 en pacientes con AOS. - Carlos O&#039;Connor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/carlosoconnor.es\/en\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Impacto de los agonistas del receptor de GLP-1 en pacientes con AOS. - Carlos O&#039;Connor\" \/>\n<meta property=\"og:description\" content=\"Esta reciente revisi\u00f3n publicada en Otolaryngology\u2013Head and Neck Surgery eval\u00faa el impacto de los agonistas del receptor de GLP-1 (como liraglutida y tirzepatida) en pacientes con AOS. Los resultados demuestran&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/carlosoconnor.es\/en\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/\" \/>\n<meta property=\"og:site_name\" content=\"Carlos O&#039;Connor\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-09T12:17:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-09T12:17:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"gestion\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"gestion\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\\\/\"},\"author\":{\"name\":\"gestion\",\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/#\\\/schema\\\/person\\\/c879dbc2b732eaa32429f50dfbd0a949\"},\"headline\":\"Impacto de los agonistas del receptor de GLP-1 en pacientes con AOS.\",\"datePublished\":\"2026-09-09T12:17:01+00:00\",\"dateModified\":\"2026-09-09T12:17:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\\\/\"},\"wordCount\":224,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/carlosoconnor.es\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/17593926592428-1024x683.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/carlosoconnor.es\\\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\\\/\",\"url\":\"https:\\\/\\\/carlosoconnor.es\\\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\\\/\",\"name\":\"Impacto de los agonistas del receptor de GLP-1 en pacientes con AOS. - Carlos O&#039;Connor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/carlosoconnor.es\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/17593926592428-1024x683.png\",\"datePublished\":\"2026-09-09T12:17:01+00:00\",\"dateModified\":\"2026-09-09T12:17:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/carlosoconnor.es\\\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\\\/#primaryimage\",\"url\":\"https:\\\/\\\/carlosoconnor.es\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/17593926592428-1024x683.png\",\"contentUrl\":\"https:\\\/\\\/carlosoconnor.es\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/17593926592428-1024x683.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/carlosoconnor.es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Impacto de los agonistas del receptor de GLP-1 en pacientes con AOS.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/#website\",\"url\":\"https:\\\/\\\/carlosoconnor.es\\\/\",\"name\":\"Carlos O&#039;Connor\",\"description\":\"Dr. Carlos O&#039;Connor Reina - Otorrinolaring\u00f3logo\",\"publisher\":{\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/carlosoconnor.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/#organization\",\"name\":\"Carlos O&#039;Connor\",\"url\":\"https:\\\/\\\/carlosoconnor.es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/carlosoconnor.es\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/cropped-logo-wide.png\",\"contentUrl\":\"https:\\\/\\\/carlosoconnor.es\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/cropped-logo-wide.png\",\"width\":241,\"height\":50,\"caption\":\"Carlos O&#039;Connor\"},\"image\":{\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/carlosoconnor.es\\\/#\\\/schema\\\/person\\\/c879dbc2b732eaa32429f50dfbd0a949\",\"name\":\"gestion\",\"sameAs\":[\"https:\\\/\\\/www.ycomieronperdices.net\\\/temp\\\/oconnor2025\"],\"url\":\"https:\\\/\\\/carlosoconnor.es\\\/en\\\/author\\\/gestion\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Impacto de los agonistas del receptor de GLP-1 en pacientes con AOS. - Carlos O&#039;Connor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/carlosoconnor.es\/en\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/","og_locale":"en_GB","og_type":"article","og_title":"Impacto de los agonistas del receptor de GLP-1 en pacientes con AOS. - Carlos O&#039;Connor","og_description":"Esta reciente revisi\u00f3n publicada en Otolaryngology\u2013Head and Neck Surgery eval\u00faa el impacto de los agonistas del receptor de GLP-1 (como liraglutida y tirzepatida) en pacientes con AOS. Los resultados demuestran&hellip;","og_url":"https:\/\/carlosoconnor.es\/en\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/","og_site_name":"Carlos O&#039;Connor","article_published_time":"2026-09-09T12:17:01+00:00","article_modified_time":"2026-09-09T12:17:06+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428.png","type":"image\/png"}],"author":"gestion","twitter_card":"summary_large_image","twitter_misc":{"Written by":"gestion","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/carlosoconnor.es\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/#article","isPartOf":{"@id":"https:\/\/carlosoconnor.es\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/"},"author":{"name":"gestion","@id":"https:\/\/carlosoconnor.es\/#\/schema\/person\/c879dbc2b732eaa32429f50dfbd0a949"},"headline":"Impacto de los agonistas del receptor de GLP-1 en pacientes con AOS.","datePublished":"2026-09-09T12:17:01+00:00","dateModified":"2026-09-09T12:17:06+00:00","mainEntityOfPage":{"@id":"https:\/\/carlosoconnor.es\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/"},"wordCount":224,"commentCount":0,"publisher":{"@id":"https:\/\/carlosoconnor.es\/#organization"},"image":{"@id":"https:\/\/carlosoconnor.es\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/#primaryimage"},"thumbnailUrl":"https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428-1024x683.png","articleSection":["Uncategorized"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/carlosoconnor.es\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/carlosoconnor.es\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/","url":"https:\/\/carlosoconnor.es\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/","name":"Impacto de los agonistas del receptor de GLP-1 en pacientes con AOS. - Carlos O&#039;Connor","isPartOf":{"@id":"https:\/\/carlosoconnor.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/carlosoconnor.es\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/#primaryimage"},"image":{"@id":"https:\/\/carlosoconnor.es\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/#primaryimage"},"thumbnailUrl":"https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428-1024x683.png","datePublished":"2026-09-09T12:17:01+00:00","dateModified":"2026-09-09T12:17:06+00:00","breadcrumb":{"@id":"https:\/\/carlosoconnor.es\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/carlosoconnor.es\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/carlosoconnor.es\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/#primaryimage","url":"https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428-1024x683.png","contentUrl":"https:\/\/carlosoconnor.es\/wp-content\/uploads\/2026\/09\/17593926592428-1024x683.png"},{"@type":"BreadcrumbList","@id":"https:\/\/carlosoconnor.es\/impacto-de-los-agonistas-del-receptor-de-glp-1-en-pacientes-con-aos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/carlosoconnor.es\/"},{"@type":"ListItem","position":2,"name":"Impacto de los agonistas del receptor de GLP-1 en pacientes con AOS."}]},{"@type":"WebSite","@id":"https:\/\/carlosoconnor.es\/#website","url":"https:\/\/carlosoconnor.es\/","name":"Carlos O&#039;Connor","description":"Dr. Carlos O&#039;Connor Reina - Otorrinolaring\u00f3logo","publisher":{"@id":"https:\/\/carlosoconnor.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/carlosoconnor.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/carlosoconnor.es\/#organization","name":"Carlos O&#039;Connor","url":"https:\/\/carlosoconnor.es\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/carlosoconnor.es\/#\/schema\/logo\/image\/","url":"https:\/\/carlosoconnor.es\/wp-content\/uploads\/2025\/07\/cropped-logo-wide.png","contentUrl":"https:\/\/carlosoconnor.es\/wp-content\/uploads\/2025\/07\/cropped-logo-wide.png","width":241,"height":50,"caption":"Carlos O&#039;Connor"},"image":{"@id":"https:\/\/carlosoconnor.es\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/carlosoconnor.es\/#\/schema\/person\/c879dbc2b732eaa32429f50dfbd0a949","name":"gestion","sameAs":["https:\/\/www.ycomieronperdices.net\/temp\/oconnor2025"],"url":"https:\/\/carlosoconnor.es\/en\/author\/gestion\/"}]}},"_links":{"self":[{"href":"https:\/\/carlosoconnor.es\/en\/wp-json\/wp\/v2\/posts\/64157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/carlosoconnor.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/carlosoconnor.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/carlosoconnor.es\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/carlosoconnor.es\/en\/wp-json\/wp\/v2\/comments?post=64157"}],"version-history":[{"count":1,"href":"https:\/\/carlosoconnor.es\/en\/wp-json\/wp\/v2\/posts\/64157\/revisions"}],"predecessor-version":[{"id":64159,"href":"https:\/\/carlosoconnor.es\/en\/wp-json\/wp\/v2\/posts\/64157\/revisions\/64159"}],"wp:attachment":[{"href":"https:\/\/carlosoconnor.es\/en\/wp-json\/wp\/v2\/media?parent=64157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/carlosoconnor.es\/en\/wp-json\/wp\/v2\/categories?post=64157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/carlosoconnor.es\/en\/wp-json\/wp\/v2\/tags?post=64157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}